Business Description
Corbus Pharmaceuticals Holdings Inc
NAICS : 325414
SIC : 2834
ISIN : US21833P1030
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1 | |||||
Equity-to-Asset | -0.24 | |||||
Debt-to-Equity | -3.03 | |||||
Debt-to-EBITDA | -0.47 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 39.6 | |||||
3-Year EPS without NRI Growth Rate | 37.5 | |||||
3-Year FCF Growth Rate | 39.9 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.74 | |||||
Quick Ratio | 0.74 | |||||
Cash Ratio | 0.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.3 | |||||
Shareholder Yield % | 0.59 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -425.8 | |||||
ROA % | -98.58 | |||||
ROIC % | -244.34 | |||||
ROC (Joel Greenblatt) % | -955.11 | |||||
ROCE % | -190.46 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -8.71 | |||||
EV-to-Forward-EBIT | -0.45 | |||||
EV-to-EBITDA | -8.83 | |||||
EV-to-Forward-Revenue | 1520.36 | |||||
EV-to-FCF | -10.97 | |||||
Earnings Yield (Greenblatt) % | -11.48 | |||||
FCF Yield % | -9.11 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Corbus Pharmaceuticals Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -9.62 | ||
Beta | 1.4 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0 | ||
20-Day SMA (€) | 3.0005 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 3.0005 - 3.0005 | ||
Shares Outstanding (Mil) | 10.51 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Corbus Pharmaceuticals Holdings Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Corbus Pharmaceuticals Holdings Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Corbus Pharmaceuticals Holdings Inc Frequently Asked Questions
What is Corbus Pharmaceuticals Holdings Inc(STU:3371)'s stock price today?
When is next earnings date of Corbus Pharmaceuticals Holdings Inc(STU:3371)?
Does Corbus Pharmaceuticals Holdings Inc(STU:3371) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |